Evolocumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1266 publications
Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.
Journal: Journal of the American Heart Association
Published: April 07, 2026
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Research Summary.
Journal: JAMA
Published: March 28, 2026
Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.
Journal: Expert opinion on pharmacotherapy
Published: March 05, 2026
In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y.
Journal: Annals of internal medicine
Published: March 02, 2026
Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspectives.
Journal: Journal of cardiovascular pharmacology
Published: February 12, 2026
Advanced therapy in familial hypercholesterolemia.
Journal: Canadian family physician Medecin de famille canadien
Published: February 12, 2026
Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial.
Journal: Diabetes, obesity & metabolism
Published: February 01, 2026
Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.
Journal: Journal of clinical medicine research
Published: January 30, 2026
PCSK9 Inhibitors in Peripheral Arterial Disease: A Systematic Review.
Journal: Annals of vascular surgery
Published: January 20, 2026
Effect of evolocumab on the gut microbiota in patients with acute myocardial infarction.
Journal: Journal of medical microbiology
Published: January 13, 2026
Last Updated: 04/28/2026